NCT05773989View on ClinicalTrials.gov

Pharmacodynamic Outcomes in CCS Patients Treated With an Individualized Treatment Strategy

PHASE4RecruitingINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

January 23, 2024

Primary Completion Date

December 1, 2024

Study Completion Date

May 1, 2025

Conditions
Coronary Artery DiseasePlatelet Reactivity
Interventions
DRUG

CYP2C19 genotype guided P2Y12 monotherapy

Patients without a LOF-allel will receive clopidogrel monotherapy (tablet of 75mg once daily) for 6 months. Patients with a LOF-allel will receive ticagrelor (tablet of 90mg twice daily) or prasugrel (tablet of 10mg once daily) for 6 months.

DRUG

Clopidogrel

Standard DAPT according to current guidelines with clopidogrel (tablet of 75mg once daily) for 6 months and acetylsalicylic acid (tablet 80mg one daily) for 6 months.

Trial Locations (1)

3435CM

RECRUITING

St. Antonius Hospital, Nieuwegein

All Listed Sponsors
lead

St. Antonius Hospital

OTHER

NCT05773989 - Pharmacodynamic Outcomes in CCS Patients Treated With an Individualized Treatment Strategy | Biotech Hunter | Biotech Hunter